San Francisco, CA – June 25, 2025 — VeriSIM Life, a leading innovator in AI-powered drug development, today announced that it has been awarded “Machine Learning Platform of the Year” in the 2025 AI Breakthrough Awards. This honor recognizes VeriSIM’s flagship platform, BIOiSIM®, for its unparalleled ability to transform drug discovery through the power of predictive modeling and translational intelligence.
BIOiSIM® is the only platform of its kind that combines mechanistic modeling with machine learning to simulate and predict how drug candidates will perform in humans—well before clinical trials begin. By integrating diverse data sources and biological models, the platform accelerates go/no-go decisions, improves candidate selection, and significantly reduces development costs and time. At its core is VeriSIM’s proprietary Translational Index™, which generates a "credit score" for any drug asset, offering pharma companies a data-driven, early-stage lens into future clinical success.
The AI Breakthrough Awards program is dedicated to recognizing the most innovative companies, technologies, and products in the global AI market today. Run by Tech Breakthrough, a leading market intelligence and recognition platform, the program received more than 2,500 nominations from over 20 countries in this year’s competition. Categories span AI infrastructure, machine learning, computer vision, natural language processing, and more, and are judged by a panel of independent experts who evaluate entries on criteria such as innovation, performance, ease of use, functionality, and impact.
“Receiving the Machine Learning Platform of the Year award from AI Breakthrough is a tremendous validation of the scientific and technological innovation at the heart of BIOiSIM,” said Dr. Varshney, Founder and CEO of VeriSIM Life. “This recognition affirms our vision to fundamentally reshape the drug development pipeline by using AI not just for automation, but for deeper understanding and better prediction of clinical outcomes. It’s a win not just for VeriSIM, but for the future of medicine.”
With growing urgency to make drug development more precise, affordable, and equitable, VeriSIM Life’s BIOiSIM® platform is uniquely positioned to help biotech and pharma organizations improve R&D productivity while advancing safer, more effective therapies to patients worldwide.
To learn more about VeriSIM Life and the BIOiSIM® platform, visit www.verisimlife.com.
AtlasGEN Novel Drug Designer efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology.
Iterative ranking of target engaging hits by their Translational Index values reduces the time and cost associated with other computational hit discovery approaches, while compressing the hit-to-lead refinement and optimization process by pre-validating hits for translatability. This unique integration dramatically reduces the number of compounds to evaluate in subsequent experimental research.
The ability to generate target engaging compound hits depends largely on the size of the molecular search library. The AtlasGEN search space is supported by more than 1 trillion compounds. Generative AI and deep learning techniques deliver unprecedented discovery capability.
AtlasGEN accurately predicts protein-lygand binding affinity by combining geometric conformer analysis with machine learning based on experimental data 72% more efficiently than molecular docking-based approaches.
.png)
